Evidence map›Paper›PMID 30171481›Full record

ReviewCurrent diabetes reports2018

Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes.

Gül Bahtiyar, Jean Pujals-Kury, Alan Sacerdote

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Medications for the treatment of obesity in adolescents.Therapeutic advances in endocrinology and metabolism · 2020
    Review
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gül BahtiyarDivision of Endocrinology, State University of New York Health Science Center, Brooklyn, NY, USA.
Jean Pujals-KuryDivision of Endocrinology, State University of New York Health Science Center, Brooklyn, NY, USA.
Alan SacerdoteDivision of Endocrinology, State University of New York Health Science Center, Brooklyn, NY, USA. Alan.Sacerdote@woodhullhc.nychhc.org.
State University of New York · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovascular system that are independent of changes in blood glucose. Cardiovascular outcome trials have demonstrated safety of GLP-1 RAs but results for cardiovascular efficacy were varied. The aim of the present review is the assessment of the effects of GLP-1 RAs on cardiovascular risk factors, and major cardiovascular events. RECENT

findingsUse of GLP-1 RAs was associated with relative risk reduction in cardiovascular mortality and all-cause mortality with no significant differences for the incidence of severe hypoglycemia, pancreatitis, pancreatic cancer, or medullary thyroid cancer when compared to placebo. Although there are differences between individual medications with respect to their effects on cardiovascular events, GLP-1 RAs offer a favorable risk-benefit profile. The present review confirms the cardiovascular safety and efficacy vs placebo of GLP-1 RAs in patients with type 2 diabetes at moderate-to-high atherosclerotic cardiovascular risk without significant side effects. Although professional guidelines recommend metformin as the sole first-line agent, GLP-1 RAs can be used as first-line therapy in individuals with type 2 diabetes who either are intolerant to metformin or have high cardiovascular risk factors.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsBiomarkersBlood PressureCardiovascular SystemDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 ReceptorHumansRisk FactorsBiomarkersGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsAlbiglutideCardiovascular outcomesCardiovascular risk factorsDulaglutideExenatideGlucagon-like peptide-1 receptor agonistsHbA1cLiraglutideLixisenatideSemaglutideType 2 diabetes

Identifiers

PMID30171481
OpenAlexW2889062210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.